Background: Although studies suggest decreased incident hepatocellular carcinoma
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancerrelated death worldwide, with chronic hepatitis C (HCV) being the most common underlying etiology in the United States and Europe. 1 Liver transplantation, surgical resection, and local ablative therapy are potentially curative and associated with excellent long-term survival but are limited by tumour recurrence exceeding 50% at 5 years. 2 Prior attempts at adjuvant pharmacologic therapy for HCC have failed to improve survival or reduce recurrence, with the exception of anti-viral therapy. 3 Interferon-based therapy was associated with a significant reduction in HCC incidence in patients with HCV-related cirrhosis as well as HCC recurrence after curative therapy. 4 The mechanism for reduction in HCC recurrence is unclear-whether related to sustained viral response (SVR) or direct interferon-related immunemediated antitumour effect. 5 This debate has become more relevant to the introduction of direct acting antiviral (DAA) therapy, which has replaced interferon-based therapy for HCV. 6 Although studies have demonstrated improvements in fibrosis and portal hypertension as well as decreased risk of incident HCC in patients with HCV-related cirrhosis, some observational studies suggest an increased risk and aggressiveness of HCC recurrence after DAA therapy. [7] [8] [9] [10] This issue remains a topic of debate, leading to uncertainty if or when to treat HCV-infected patients with a history of HCC. 11, 12 These data have created fear among patients receiving DAA therapy and prompted some providers to withhold HCV treatment from patients with a history of HCC. The European Medicine Agency's Pharmacovigilance Risk Assessment Committee has required high quality data evaluating this association. Given the lack of randomised data evaluating this association, we are forced to rely on cohort studies and indirect comparisons across studies. The aim of this systematic review is to characterize HCC recurrence patterns following DAA-based therapy.
| ME TH ODS

| Literature search and study selection
We searched MEDLINE and SCOPUS databases from January 1, 2015
through December 1, 2017 using search terms: (liver ca$ or hepatocellular ca$ or hcc or hepatoma) and (hepatitis C or HCV) and (interferonfree or direct-acting antiviral or DAA). We also manually searched or prospective but were required to report the proportion of patients with recurrence after DAA therapy. Additional exclusion criteria included (1) non-English language, (2) nonhuman data, and (3) lack of original data. If publications reported data using the same cohort of patients, the study with more complete data was included.
| Data extraction
Two authors (N.S. and A.S.) independently reviewed and extracted required information from eligible studies using standardised forms. A third investigator (N.P.) was available to resolve any discrepancies between the sets of extracted data. The data extraction form included the following study design items: geographical location and date of study, study design (prospective vs retrospective), characteristics and size of study cohort, inclusion and exclusion criteria, HCC treatment regimen, median time from HCC treatment to DAA treatment, and duration of follow-up. In addition, the extraction form recorded the following primary data: proportion of patients with HCC recurrence and patterns of recurrence (ie, tumour burden and HCC-directed treatment). Two authors (N.S. and A.S.) independently assessed study quality using a modified checklist based upon a modified version of the Newcastle-Ottawa quality assessment scale, with discrepancies resolved by consensus. 14 Studies with <1 year of follow-up or loss to follow-up exceeding 5% were regarded as high risk of bias.
| Statistical analysis
The aim of this study was to characterize HCC recurrence patterns after DAA therapy. For each individual study, the proportion of patients with HCC recurrence with 95% confidence intervals was calculated. Estimates of effect were pooled using a binomial-normal model and the DerSimonian and Laird method for a random effects model. Heterogeneity was initially evaluated graphically by examination of forest plots and statistically by the inconsistency index (I   2   ) , with values >50% consistent with the possibility of substantial heterogeneity. 15 Subgroup analyses were planned for HCC detection for predefined subsets of studies based on (i) prospective vs retrospective study design, (ii) study location, (iii) duration of follow-up (iv) timing of DAA initiation, and (v) availability of full text manuscripts. We assessed for presence of heterogeneity between subgroups, with statistical significance defined as P < 0.05. We also performed a subgroup analysis among studies reporting early HCC recurrence after DAA initiation.
We performed univariate and multivariate meta-regression analyses to evaluate the potential association between study-level covariates 
| Study characteristics
Characteristics of the 24 studies (ie, 25 cohorts) reporting the absolute proportion of patients with HCC recurrence after DAA therapy are described in Table 1 . The majority of cohorts were retrospective (n = 19) and only available as abstracts or letters to the editor (n = 14). Thirteen cohorts were conducted in Europe, 10 in Asia, and 2 in the United States. Studies included a total of 1820 DAA-treated patients, although most cohorts (n = 19) included less than 100 patients, resulting in imprecise estimates for HCC recurrence with wide confidence intervals. Most patients had achieved HCC complete response after resection or ablation; however, 25%-50% of patients in some studies had received noncurative therapies, including transarterial chemoembolisation (TACE). Duration of follow-up to assess recurrence ranged from 3 to 36 months, although some studies defined recurrence from date of HCC treatment and others evaluated recurrence from date of DAA initiation. Although most studies only included single-arm cohorts, 7 of the studies included a comparator arm of interferon-treated and/or untreated patients. Two additional studies did not report the absolute proportion of patients with HCC recurrence but compared relative recurrence between DAA-treated patients and interferon-treated or untreated patients, yielding a total of 9 comparative studies (Table 2 ).
| HCC recurrence following DAA therapy
The pooled point estimate for HCC recurrence following DAA therapy was 25.1% (95% CI: 19.4%-31.2%); however, there was significant statistical heterogeneity (I 2 = 86%) ( Figure 1 ). The proportion of patients with HCC recurrence varied widely between studies, ranging from 0% to 59% within 2 years ( Nine studies compared HCC recurrence in DAA-treated (n = 947) patients to interferon-treated (n = 210) and/or untreated (n = 641) patients (Table 2) . 22, 24, 30, 32, 34, 37, 40, 41 Five studies reported no significant difference in HCC recurrence between DAA-treated and untreated patients in multivariable analyses, while 2 studies found significantly lower HCC recurrence among DAA-treated patients. Among the 5 studies reporting relative risk of recurrence with 95% confidence intervals, DAA-treated patients had a lower pooled recurrence risk than untreated patients (OR: 0.55, 95% CI:
0.25-0.85). All 3 studies comparing DAA-treated and interferon-treated patients reported no difference in HCC recurrence between the 2 groups; however, only unadjusted analyses were reported.
| HCC recurrence patterns
Patterns of HCC recurrence including tumour burden and HCCdirected treatment after DAA therapy are detailed in lesions and 60%-70% for 1-2 cm lesions. 48 Given the lack of urgency for HCV therapy after HCC complete response, it appears prudent to wait at least 6 months after HCC complete response to initiate DAA Notably, most studies to date are single-arm, retrospective cohort studies with clinical heterogeneity in tumour burden, HCC treatments leading to complete response, and follow-up periods.
When interpreting the proportion of patients with HCC recurrence in these single arm studies, it is important to consider the natural history of HCC after complete response, in which many patients will have HCC recurrence independent of DAA therapy. HCC recurrence after complete response can vary substantially depending on which HCC-directed treatment received. While surgical resection and local ablative therapies are considered curative, recurrence rates approach 25%-35% within the first year and 50%-60% within 2 years. 44, 49, 50 Further, up to 25%-50% of patients in some studies received TACE, which is typically not curative and associated with a high risk of recurrence. 51 Further, patients with high-risk tumour characteristics (eg, multifocal HCC or elevated AFP) have higher recurrence rates than their counterparts; however, specific data regarding these risk factors and subgroup analyses were not reported in many studies.
In addition to concerns about clinical heterogeneity within study populations, we noted potential for misclassification and These limitations highlight the need for high-quality prospective studies with strict inclusion criteria and a standardised surveillance protocol. Although comparative studies suggest recurrence rates among DAA-treated patients may be similar to interferon-treated and untreated patients, these analyses are limited by potential for confounders such as degree liver dysfunction. These studies can also be limited by immortal time bias, as patients with early recurrence would typically not receive DAA treatment and therefore would be over-represented in the untreated group. Given the high prevalence of limitations in study design, we propose minimum criteria for future studies in this area (Table 5) . Waziry and colleagues also included cohorts evaluating posttransplant recurrence, but we excluded these studies given posttransplant recurrence could be driven by a different mechanism.
Finally, our study also characterised patterns of HCC recurrence and highlighted limitations of available data, which informed our recommendations for minimum reporting criteria.
Although our study provides a comprehensive summary of current with differential reporting and meta-analysis of these factors was not possible. In addition, we excluded non-English studies due to practical considerations, which may further bias the results.
In summary, there are conflicting data about the potential for increased HCC recurrence after DAA therapy; however, most studies have methodological limitations. Ongoing multi-centre retrospective and prospective studies should provide some insight into this controversial issue; we highlighted some suggested minimum reporting requirements to avoid the pitfalls of current studies. While awaiting these data, it is likely prudent to wait at least 6 months after HCC complete response before initiating DAA therapy.
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